Imunon Inc (IMNN)vsMerck & Company Inc (MRK)
IMNN
Imunon Inc
$2.10
-1.87%
HEALTHCARE · Cap: $8.66M
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 52614302% more annual revenue ($65.77B vs $125,000). MRK leads profitability with a 13.6% profit margin vs 0.0%. IMNN appears more attractively valued with a PEG of 5.03. MRK earns a higher WallStSmart Score of 50/100 (D+).
IMNN
Avoid23
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IMNN.
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IMNN
The strongest argument for IMNN centers on Debt/Equity.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : IMNN
The primary concerns for IMNN are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
IMNN carries more volatility with a beta of 1.93 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Imunon Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Imunon Inc. is a clinical-stage biotechnology company specializing in the development of innovative immune-mediated therapies for cancer and infectious diseases. Leveraging its proprietary INFECT platform, Imunon aims to enhance immune responses that promote effective tumor eradication. With a diverse pipeline of therapeutics undergoing various stages of clinical evaluation and established strategic collaborations, the company is poised to make significant contributions to the field of immunotherapy, potentially transforming patient outcomes and solidifying its competitive position within the biopharmaceutical landscape.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?